Commentary

Video

Dr Lawrence Eichenfield Hopeful for New Pediatric AD Treatment Option

Lawrence Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children's Hospital in San Diego, shared the implications of the findings from INTEGUMENT-PED, the phase 3 study assessing the efficacy and safety of once-daily roflumilast cream 0.05% in pediatric patients with atopic dermatitis (AD), for future clinical practice.

This content was produced independently by The American Journal of Managed Care® (AJMC®) and is not endorsed by the American Academy of Dermatology.

At the 2024 American Academy of Dermatology Annual Meeting, Lawrence Eichenfield, MD, chief of pediatric dermatology at Rady Children's Hospital in San Diego and professor of dermatology and pediatrics at the University of California, San Diego, presented late-breaking findings from the INTEGUMENT-PED phase 3 randomized controlled trial of roflumilast cream 0.05% in children 2 to 5 years of age with atopic dermatitis (AD).

In an interview with AJMC, Eichenfield said that roflumilast cream 0.05% had positive results in pediatric patients with AD in terms of efficacy and safety. He noted that he is looking forward to roflumilast cream being "hopefully approved" and "potentially having this in our armamentarium for treating young children."

Transcript

How do the results of the INTEGUMENT-PED study contribute to our understanding of AD treatment options for young children? What implications might they have for clinical practice and future research?

First, to go through some of the basics, the study hit the sort of standard outcome measures that we look for. What percentage of patients made it to clear or almost cleared? About 25% of those were within a 4-week time period with once-a-day application with a big delta, or almost 15% delta, between the vehicle.

It was very interesting to me that a lot of the population that got that clear, or almost clear, were already clear or almost clear by 2 weeks, and there was almost 80 something percent of those because it was 21% of the patients made clear or almost clear at week 2.

The secondary outcome measures being clear or almost clear at EASI [Eczema Area and Severity Index] 75, and the percentage of patients who had at least a 4-part drop in itch as compared to their baseline was consistent with a nice separation from the vehicle cream throughout the course of the study.

When we looked very early, the improvement in the itch with roflumilast was seen as early as 24 hours after the first application. So, it was a very rapid separation of itch scores from the vehicle.

Overall, I think having this move forward and hopefully be approved as a new nonsteroidal, which is very well formulated, can be helpful in our care of patients with atopic dermatitis. We show in this case that it helped to improve eczema in 2- to 5-year-olds with early clinical responses and very good tolerance levels. So, we look forward to potentially having this in our armamentarium for treating young children.

Related Videos
A panel of 4 experts on PDTs
A panel of 4 experts on PDTs
A panel of 5 experts on Alzheimer disease
A panel of 5 experts on Alzheimer disease
Monica Kraft, MD, ATSF.
Video 2 - "SunRISe-1: Examining Combination Therapy for HR NMIBC"
Video 1 - "Comparing Long-Term Efficacy of Bladder-Preserving Therapies for NMIBC "
Michael Arzt, MD.
Ravin Ratan, MD, MEd, MD Anderson
Dr Ajay Goel
Related Content
CH LogoCenter for Biosimilars Logo